Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Humacyte, Inc.
  6. News
  7. Summary
    HUMA   US44486Q1031

HUMACYTE, INC.

(HUMA)
  Report
Delayed Nasdaq  -  04:00 2022-12-06 pm EST
3.020 USD   -6.79%
12/02Humacyte Human Acellular Vessel Ukraine Humanitarian Results to be Presented at Multiple Vascular Conferences in December 2022
AQ
12/01Humacyte Human Acellular Vessel™ (HAV™) Ukraine Humanitarian Results to be Presented at Multiple Vascular Conferences in December 2022
AQ
11/23Humacyte to Present at the 34th Annual Piper Sandler Healthcare Conference
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stock Gain Pre-Bell Friday

09/02/2022 | 09:19am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
HUMACYTE, INC. -6.79% 3.02 Delayed Quote.-58.34%
NASDAQ COMPOSITE -2.00% 11014.89 Real-time Quote.-29.59%
PHILIPS NV -1.02% 13.56 Real-time Quote.-58.18%
QUALIGEN THERAPEUTICS, INC. -1.83% 1.61 Delayed Quote.-84.95%
RS GROUP PLC -2.59% 914.64 Delayed Quote.-22.14%
All news about HUMACYTE, INC.
12/02Humacyte Human Acellular Vessel Ukraine Humanitarian Results to be Presented at Multipl..
AQ
12/01Humacyte Human Acellular Vessel™ (HAV™) Ukraine Humanitarian Results to be ..
AQ
11/23Humacyte to Present at the 34th Annual Piper Sandler Healthcare Conference
AQ
11/10HUMACYTE, INC. Management's Discussion and Analysis of Financial Condition and Results..
AQ
11/10Transcript : Humacyte, Inc., Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10Humacyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sep..
CI
11/10Humacyte Third Quarter 2022 Financial Results and Business Update
AQ
11/07Humacyte Presents Six-Month Human Acellular Vessel™ (HAV™) Coronary Artery ..
AQ
11/03Humacyte to Present Third Quarter Financial Results and Provide Corporate Updateáon Nov..
AQ
09/23Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Ve..
AQ
More news
Analyst Recommendations on HUMACYTE, INC.
More recommendations
Financials (USD)
Sales 2022 1,77 M - -
Net income 2022 -33,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -9,44x
Yield 2022 -
Capitalization 311 M 311 M -
Capi. / Sales 2022 176x
Capi. / Sales 2023 201x
Nbr of Employees 146
Free-Float 51,8%
Chart HUMACYTE, INC.
Duration : Period :
Humacyte, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 3,02 $
Average target price 10,13 $
Spread / Average Target 235%
EPS Revisions
Managers and Directors
Laura E. Niklason President, Chief Executive Officer & Director
Dale A. Sander Chief Financial Officer & Treasurer
Kathleen Sebelius Chairman
Shamik J. Parikh Chief Medical Officer
Heather Prichard Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
HUMACYTE, INC.-58.34%311
MODERNA, INC.-31.67%66 671
IQVIA HOLDINGS INC.-25.61%38 981
LONZA GROUP AG-36.87%37 974
ALNYLAM PHARMACEUTICALS, INC.33.39%27 022
SEAGEN INC.-23.73%21 892